Folliculotropic Mycosis Fungoids Responding to Bexarotene Gel

February 2008 | Volume 7 | Issue 2 | Case Reports | 169 | Copyright © February 2008

Hobart W. Walling MD PhD, Brian L Swick MD, Pedram Gerami MD, Richard K. Scupham MD PhD

Abstract
Folliculotropic mycosis fungoides (FMF) is an uncommon and potentially aggressive form of cutaneous T cell lymphoma (CTCL). Phototherapy, radiotherapy, and systemic chemotherapy are the most commonly employed treatment options, but may have limited success and common adverse reactions. Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FMF. The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.